Page 101 - Read Online

Page 10 of 11 Dixit et al. J Cancer Metastasis Treat 2022;8:47 https://dx.doi.org/10.20517/2394-4722.2022.70

12. Zhang Q, Wang Z, Cai H, et al. CircPLK1 acts as a carcinogenic driver to promote the development of malignant pleural
mesothelioma by governing the miR-1294/HMGA1 pathway. Biochem Genet 2022;60:1527-46. DOI PubMed
13. Xu Y, Zheng M, Merritt RE, et al. miR-1 induces growth arrest and apoptosis in malignant mesothelioma. Chest 2013;144:1632-43.
DOI PubMed PMC
14. Amatya VJ, Mawas AS, Kushitani K, Mohi El-Din MM, Takeshima Y. Differential microRNA expression profiling of mesothelioma
and expression analysis of miR-1 and miR-214 in mesothelioma. Int J Oncol 2016;48:1599-607. DOI PubMed
15. Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent
mutations, gene fusions and splicing alterations. Nat Genet 2016;48:407-16. DOI PubMed
16. Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and
CUL1 in malignant pleural mesothelioma. Cancer Res 2015;75:264-9. DOI PubMed
17. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine
phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003;9:2108-13. PubMed
18. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science
2004;303:844-8. DOI
19. Liu J, Zhang C, Zhao Y, Feng Z. MicroRNA Control of p53. J Cell Biochem 2017;118:7-14. DOI
20. Andersen M, Grauslund M, Ravn J, Sørensen JB, Andersen CB, Santoni-Rugiu E. Diagnostic potential of miR-126, miR-143, miR-
145, and miR-652 in malignant pleural mesothelioma. J Mol Diagn 2014;16:418-30. DOI PubMed
21. Cioce M, Ganci F, Canu V, et al. Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma. Oncogene 2014;33:5319-
31. DOI PubMed PMC
22. Singh A, Bhattacharyya N, Srivastava A, et al. MicroRNA-215-5p treatment suppresses mesothelioma progression via the MDM2-
p53-signaling axis. Mol Ther 2019;27:1665-80. DOI PubMed PMC
23. Williams M, Cheng YY, Kirschner MB, et al. Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural
mesothelioma. Oncotarget 2019;10:4125-38. DOI PubMed PMC
24. Williams M, Cheng YY, Phimmachanh M, Winata P, van Zandwijk N, Reid G. Tumour suppressor microRNAs contribute to drug
resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways. Cancer Drug Resist 2019;2:1193-206. DOI
PubMed PMC
25. Pinelli S, Alinovi R, Corradi M, et al. A comparison between the effects of over-expression of miRNA-16 and miRNA-34a on cell
cycle progression of mesothelioma cell lines and on their cisplatin sensitivity. Cancer Treat Res Commun 2021;26:100276. DOI
PubMed
26. Menges CW, Kadariya Y, Altomare D, et al. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched
cancer stem cells via a p53-miR-34a-c-Met axis. Cancer Res 2014;74:1261-71. DOI PubMed PMC
27. Kubo T, Toyooka S, Tsukuda K, et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of
malignant pleural mesothelioma. Clin Cancer Res 2011;17:4965-74. DOI PubMed
28. Maki Y, Asano H, Toyooka S, Soh J, Kubo T, Katsui K, Ueno T, Shien K, Muraoka T, Tanaka N, Yamamoto H, Tsukuda K,
Kishimoto T, Kanazawa S, Miyoshi S. MicroRNA miR-34b/c enhances cellular radiosensitivity of malignant pleural mesothelioma
cells. Anticancer Res 2012;32:4871-5. PubMed
29. Ueno T, Toyooka S, Fukazawa T, et al. Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma. Acta
Med Okayama 2014;68:23-6. DOI PubMed
30. Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulm Med 2021;21:148.
DOI PubMed PMC
31. Cantini L, Belderbos RA, Gooijer CJ, et al. Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch
expanded access program. Transl Lung Cancer Res 2020;9:1169-79. DOI PubMed PMC
32. Okada M, Kijima T, Aoe K, et al. Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese
phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 2019;25:5485-92. DOI PubMed
33. Reid G, Pel ME, Kirschner MB, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural
mesothelioma. Ann Oncol 2013;24:3128-35. DOI PubMed
34. Kao SC, Cheng YY, Williams M, et al. Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant
pleural mesothelioma. J Thorac Oncol 2017;12:1421-33. DOI PubMed
35. van Zandwijk N, Pavlakis N, Kao SC, et al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant
pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol 2017;18:1386-96. DOI PubMed
36. Williams M, Kirschner MB, Cheng YY, et al. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
Oncotarget 2015;6:23480-95. DOI PubMed PMC
37. Santarelli L, Strafella E, Staffolani S, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant
mesothelioma. PLoS One 2011;6:e18232. DOI PubMed PMC
38. Tomasetti M, Nocchi L, Staffolani S, et al. MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering
with the mitochondrial function. Antioxid Redox Signal 2014;21:2109-25. DOI PubMed PMC
39. Tomasetti M, Monaco F, Manzella N, et al. MicroRNA-126 induces autophagy by altering cell metabolism in malignant
mesothelioma. Oncotarget 2016;7:36338-52. DOI PubMed PMC
40. Singh A, Pruett N, Pahwa R, Mahajan AP, Schrump DS, Hoang CD. MicroRNA-206 suppresses mesothelioma progression via the Ras